Skip to main content

Table 1 Demographic and clinical data of patients with AD and controls

From: The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease

  AD baseline
(n = 322)
AD 1-year follow-up
(n = 244)
AD 2-year follow-up
(n = 166)
Controls
(n = 88)
P value*
Male patients, n (%) 173 (53.7%) 128 (52.4%) 86 (51.8) 54 (61.4%) 0.19
Age (years) 80.4 (6.2) 80.3 (6.2) 79.6 (6.5) 77.0 (6.2) <0.01
Education (years) 10.1 (4.4)    10.1 (5.1) 0.96
Disease duration (months) 52.4 (47.5)   
BMI (kg/m2) 23.6 (3.4) 23.7 (3.3) 23.9 (3.3) 24.4 (3.2) 0.07
MMSE 18.1 (5.9) 16.7 (6.4) 16.5 (6.6) 27.2 (2.5) <0.01
Delayed recall of 12-item memory test 1.1 (1.8)     
Forward digit span 8.5 (3.2)    
Backward digit span 3.9 (2.1)    
Category verbal fluency 6.1 (3.0)    
Modified Boston naming test 11.1 (3.1)    
CDR, n (%)
 0.5 20 (6.2%) 10 (4.1%) 6 (3.6%)   
 1 208 (64.6%) 129 (52.9%) 74 (44.6%)  
 2 81 (25.2%) 81 (33.2%) 65 (39.2%)  
 3 12 (3.7%) 23 (9.4%) 19 (11.4%)  
NPI-agitation/aggression 7.0 (12.0) 7.9 (12.5) 6.9 (11.4)  
NPI-mood 5.4 (9.4) 6.4 (9.9) 5.3 (8.6)  
NPI-frontal 5.7 (10.1) 7.2 (11.4) 5.7 (8.4)  
ApoE4 carrier, n (%) 135 (41.9%)    9 (10.2%) < 0.01
Plasma clusterin level (μg/ml) 248.6 (37.9)    243.8 (35.9) 0.29
Aβ1–40 (pg/ml) 157.9 (50.7)    144.5 (36.9) 0.02
Aβ1–42 (pg/ml) 36.9 (20.8)    34.1 (9.1) 0.23
Ratio of Aβ1–42/Aβ1–40 (%) 23.7 (8.7)    24.4 (6.7) 0.32
  1. Values are shown as means and standard deviations unless otherwise indicated
  2. *Comparison between AD baseline and controls by Independent two sample t tests or Chi-square tests
  3. amyloid beta, AD Alzheimer’s disease, ApoE apolipoprotein E, BMI body mass index, CDR Clinical Dementia Rating, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory